Bridgebio Pharma, Inc. operates as a bio technology company. The Company focuses on development of medicines for genetic diseases. Bridgebio Pharma serves patients worldwide.

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bridgebio Pharma Inc (BBIO US)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Current Report (Form 8-K | Period ending 2024-08-01)

Current Report (Form 8-K | Period ending 2024-07-23)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)